Graves' Disease Market

 Market Overview:

The 7 major Graves' disease markets are expected to exhibit a CAGR of 3.57% during 2024-2034.

The Graves' disease market has been comprehensively analyzed in IMARC's new report titled "Graves' Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Graves' disease is an autoimmune illness that affects the thyroid gland and causes an overproduction of thyroid hormones. This condition is more common in women and usually affects between the age of 20 to 50 years. Some of the prevalent symptoms of Graves' disease are rapid heartbeat, sweating, weight loss, nervousness, fatigue, irritability, etc. Additionally, a few patients may also develop an enlarged thyroid gland, red and swollen eyes, and experience changes in skin and hair. Graves' disease is typically diagnosed using a combination of physical examination, blood testing, and imaging investigations. A physical examination may indicate an enlarged thyroid gland as well as other hyperthyroidism symptoms, such as rapid heartbeat and excessive sweating. Blood tests are used to measure the levels of thyroid hormones and antibodies in the blood. Furthermore, numerous imaging tests, including ultrasound and radioactive iodine uptake, may be utilized to visualize the thyroid gland and determine the extent of the overproduction of hormones.

The growing prevalence of autoimmune disorders and the escalating need for efficient treatments with improved outcomes are primarily augmenting the global Graves' disease market. In addition to this, the widespread adoption of immunosuppressive therapy, such as glucocorticoids, to suppress the immune system and prevent it from attacking the thyroid gland is also acting as a significant growth-inducing factor. Moreover, the increasing utilization of beta-blockers to control the symptoms of Graves' disease, including rapid heartbeat, tremors, anxiety, etc., by blocking the effects of thyroid hormones on the body is further creating a positive outlook for the market. Apart from this, several key players are making extensive investments in developing immunomodulatory drugs that target the underlying autoimmune process of Graves' disease. This, in turn, is also propelling the market growth. Additionally, the emerging popularity of radioactive iodine therapy among patients with severe symptoms or who cannot take anti-thyroid medications is further augmenting the market growth. Besides this, the growing preference for minimally invasive therapies, such as radiofrequency ablation and laser ablation, owing to their numerous advantages over traditional surgical treatments, including shorter recovery times, fewer complications, and lower risks of damage to surrounding tissues, is expected to drive the global Graves' disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Graves' disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Graves' disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Graves' disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Graves' disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Graves' disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Graves' disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Graves' disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Graves' disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Graves' disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Graves' disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Graves' disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Graves' disease by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Graves' disease by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with Graves' disease across the seven major markets?
• What is the size of the Graves' disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Graves' disease?
• What will be the growth rate of patients across the seven major markets?
   

Graves' Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Graves' disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Graves' disease market?
• What are the key regulatory events related to the Graves' disease market?
• What is the structure of clinical trial landscape by status related to the Graves' disease market?
• What is the structure of clinical trial landscape by phase related to the Graves' disease market?
• What is the structure of clinical trial landscape by route of administration related to the Graves' disease market?